ENALAPRIL VERSUS BENDROFLUMETHIAZIDE IN TYPE-2 DIABETES COMPLICATED BY HYPERTENSION

In a double-blind, double-dummy, randomized, multi-centre study, the e ffects of bendroflumethaizide vs. enalapril on blood pressure, glycaem ic control, lipoprotein concentrations and albuminuria were compared i n non-proteinuric, hypertensive type 2 diabetic patients; they were tr eated for 20 weeks with either bendroflumethiazide 2.5-5.0 mg (n = 59) or enalapril 10-20 mg (n = 55). Age, fasting plasma glucose, HbA(1C) and BMI were similar in the groups. Systolic and diastolic blood press ure were reduced in both groups. Bendroflumethiazide was accompanied b y minor but significant elevations in fasting plasma glucose and serum C-peptide. HbA(1c) was increased during both treatments. Lipoproteins and urinary albumin/creatinine ratio were stable. Bendroflumethiazide caused a decrease in serum potassium and an increase in serum urate. No significant correlations were observed between the decline in blood pressure and changes in the metabolic risk factors. Baseline levels o f age, sex, EMI, blood pressure or urinary albumin/creatinine ratio we re not related to changes in blood pressure, metabolic parameters or u rinary albumin/creatinine ratio.